{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 33,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a timeline framework to communicate both past achievements and future R&D milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/6",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.78
      },
      "kind": "callout",
      "text": "$304M in cash as of September 30, 2022, plus access to up to an additional $160M from Hercules term loan facility, provides runway expected into 2025",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9167663-72cf-4806-ac70-c7572fa67ff5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.88,
        "x": 0.06,
        "y": 0.26
      },
      "kind": "framework",
      "text": "Achieved and expected milestones",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f648f487-b6ae-4423-b49a-d5ccd87a39d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.23,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "list",
      "text": "Key achievements to date: Initiation of 8 clinical programs, COMP360 Phase 2b results, RL-007 Phase 2a results, GRX-917 Phase 1 results",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33c1f09a-cfb8-47a8-9033-1b7cb7a78584",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.06,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: PoC = Proof of Concept. 1. Based on current expectations and projections as of the date of this presentation, and subject to change. 2. Total facility size is up to $175M, with $15M drawn to-date (in Q3 2022). Unless otherwise stated, this presentation is updated as of January 6th, 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5e5b759-0e66-4146-9f1a-eb00cfa60bfe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "We expect to deliver several meaningful R&D milestones anticipated across our key programs through 2024 with cash runway into 2025",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e620211-4653-46c3-b225-7fa739698cc1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "dd3c6c8e-4e73-41f0-a072-a326f5f242c1",
      "evidence": "The slide presents a chronological sequence of R&D milestones across H1'23, H2'23, and 2024.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "2bf82b33-c322-4f04-aa0f-63d81653966f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck presents a roadmap for atai Life Sciences, including expected milestones and cash runway into 2025.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}